Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
BioNTech (Nasdaq:BNTX) reported Q2 2026 revenues of €105.6 million, down from €260.8 million, and a net loss of €820.8 million (adjusted net loss €562.3 million; diluted loss per share €3.24, adjusted €2.22). Year‑to‑date revenues were €223.7 million with a net loss of €1,352.7 million.
BioNTech revised 2026 revenue guidance to €1.6–1.9 billion (from €2.0–2.3 billion) and lowered adjusted R&D guidance to €2.0–2.3 billion, keeping adjusted SG&A at €700–800 million. Cash, cash equivalents and security investments totaled €16.6 billion, and a share repurchase program of up to $1.0 billion is underway. The company highlighted 14 ongoing pivotal trials, multiple late‑stage oncology milestones, approval of an XFG variant‑adapted COVID‑19 vaccine in the EU, and the appointment of Guido Oelkers as CEO effective by February 1, 2027.
BioNTech (Nasdaq: BNTX) announced that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer, with his start date set for no later than February 1, 2027. He will succeed co-founder Prof. Ugur Sahin, M.D., who currently serves as CEO. Oelkers joins from Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum (Sobi), where he has been CEO since 2017 and, according to BioNTech, more than quadrupled revenues over nine financial years (2017–2026) while increasing profitability and strengthening the late-stage pipeline. The Supervisory Board describes him as an experienced strategic leader in biotechnology and pharmaceuticals with a strong track record in scaling innovation-driven organizations, particularly in oncology, immunology and the U.S. market.
BioNTech characterizes the CEO appointment as the outcome of a comprehensive selection process and part of a pivotal phase as it seeks to transition its diversified, late-stage oncology pipeline into multiple approved products by 2030. Prof. Sahin plans to actively support Oelkers’ onboarding to ensure a smooth handover, while he and Chief Medical Officer Prof. Özlem Türeci, M.D., are set to manage a new independent company. The search for a new CMO is ongoing, focusing on candidates with strong medical, scientific and late-stage development experience.
BioNTech (Nasdaq: BNTX) and Pfizer announced that the European Commission has granted marketing authorization for their 2026-2027 monovalent XFG-adapted COVID-19 vaccine for individuals aged 6 months and older. The decision follows EMA Emergency Task Force and CHMP recommendations to update vaccines to target the XFG variant of the JN.1 lineage, with supporting clinical, non-clinical and real-world data showing strong immune responses against circulating lineages including XFG, XFG.1.1, NB.1.8.1, PQ.17 and PQ.2.8.1.
The authorization applies across all 27 EU Member States plus Iceland, Liechtenstein and Norway. Pfizer and BioNTech have begun “at-risk” manufacturing and expect shipping to start soon, supplying countries via the EC contract or national arrangements. The companies note more than five billion doses of their COVID-19 vaccines have been distributed globally and provide extensive safety information, including rare risks of severe allergic reactions, myocarditis and pericarditis.
BioNTech (Nasdaq: BNTX) will release its second quarter 2026 financial results on Tuesday, August 4, 2026. On the same day at 8:00 a.m. ET (2:00 p.m. CET), the company will host a conference call and webcast to discuss results and provide a corporate update.
BioNTech (Nasdaq:BNTX) and Bristol Myers Squibb reported interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 trial of bispecific immunomodulator pumitamig plus chemotherapy in first-line advanced non-small cell lung cancer.
The regimen showed confirmed objective response rates up to 72.7% by subtype and up to 100% at high PD-L1 expression, with a 100% disease control rate and a manageable safety profile, and is now being advanced in three global Phase 3 NSCLC trials.
BioNTech (Nasdaq:BNTX) will present new data from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting in Chicago, May 29–June 2.
Key highlights include interim Phase 2/3 ROSETTA Lung-02 data for pumitamig in first-line NSCLC and Phase 2 PRESERVE-004 overall survival data for gotistobart in platinum-resistant ovarian cancer, plus multiple ADC and novel-novel combination trial updates across more than 25 Phase 2/3 studies, including 13 pivotal trials.
BioNTech (Nasdaq:BNTX) held its 2026 Annual General Meeting, with 92% of share capital represented and all agenda items approved by shareholders.
The Supervisory Board was expanded from six to eight members, adding oncology and commercialization expertise, with Helmut Jeggle elected Chairman and several member mandates extended.
BioNTech (Nasdaq: BNTX) authorized a new ADS repurchase program to buy up to $1.0 billion of American Depositary Shares through May 6, 2027. Repurchases will be funded from existing cash resources and may be executed in open-market transactions, with the company citing capital-allocation discipline and Rule 10b-18/10b5-1 safe-harbor compliance.
BioNTech expects repurchased ADSs to satisfy ordinary-course obligations and says the Program aims to enhance capital efficiency while preserving financial flexibility to support its multi-product objective by 2030.
BioNTech (Nasdaq: BNTX) reported Q1 2026 results: revenues €118.1m, net loss €531.9m (adjusted €494.6m), and cash, cash equivalents and investments €16.8bn. The company initiated five pivotal pumitamig trials, expects six late‑stage readouts in 2026, reaffirmed 2026 revenue guidance of €2.0–2.3bn, announced a $1.0bn ADS buyback program, and plans manufacturing consolidations affecting ~1,860 roles with estimated recurring savings of ~€500m by 2029.
BioNTech (Nasdaq: BNTX) will report first quarter 2026 financial results on May 5, 2026 and host a conference call and webcast at 8:00 a.m. ET / 2:00 p.m. CET.
Investors should register in advance to receive dial‑in numbers and a PIN; slides and audio will be available on the company website and a replay will be archived for 30 days.